Studies find existing and experimental drugs active against MERS-coronavirus

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

In the first study, researchers screened a library of 290 , either FDA-approved or in advanced for antiviral activity against the MERS coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV) in cell culture. They found 27 compounds that were active against both viruses including some cancer drugs and antipsychotics.

"Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to the normal paradigm of huge library screening against a specific viral enzyme," says author Matthew Frieman of the University of Maryland Medical School. "Given development times and manufacturing requirements for new products, repurposing of existing drugs is likely the best solution to rapidly identify therapeutics for outbreaks due to emerging viruses."

Researchers from the National Institutes of Health, the United States Army Medical Research Institute of Infectious Diseases and Zalicus Inc., Cambridge MA, were also involved in the study. A copy of the manuscript can be found online at http://bit.ly/asmtip0514e.

In the second study, researchers collaborating in the European antiviral research program SILVER used a similar methodology to screen a library of 348 FDA-approved drugs for anti-MERS-CoV activity in cell culture. They identified four compounds that inhibited MERS-CoV, SARS-CoV and Human Coronavirus 229E at relatively low concentrations. Two of the compounds were also identified by the U.S. study: the antimalarial drug chloroquine and the antipsychotic chlorpromazine.

"Although their therapeutic potential (alone or in combination) remains to be assessed in animal models, our findings may offer a starting point for treatment of patients infected with zoonotic coronaviruses like MERS-CoV," says corresponding author Eric Snijder of Leiden University Medical Center, the Netherlands. Researchers from the Rega Institute for Medical Research in Leuven, Belgium and the Erasmus Medical Center in Rotterdam, the Netherlands were also involved in the study.

A copy of the manuscript can be found online at http://bit.ly/asmtip0514f.

The third and final study finds that an experimental compound, previously shown to block SARS-CoV replication, can inhibit replication of two other coronaviruses, MERS-CoV and mouse hepatitis virus.

"This study shows that it is possible to target multiple coronaviruses through broad-spectrum inhibitors," says corresponding author Stefan Sarafianos of the Bond Life Sciences Center at the University of Missouri, an author on the study. "This compound could serve as a lead for the development of effective broad-spectrum anti-coronavirus drugs."

More information: Researchers from the University of Maryland Medical School and the University of Pennsylvania School of Medicine also contributed to the research. The manuscript can be found online at bit.ly/asmtip0514g

add to favorites email to friend print save as pdf

Related Stories

Saudi MERS death toll reaches 115

May 05, 2014

Saudi health authorities announced on Monday that the death toll from the MERS coronavirus has reached 115 since the respiratory disease first appeared in the kingdom in 2012.

Saudi MERS death toll rises to 126

May 09, 2014

Saudi Arabia's death toll from MERS has risen by five to 126 fatalities since the mystery respiratory virus first appeared in the kingdom in 2012, the health ministry said Friday.

Recommended for you

Medical charity: Time running out to stop Ebola

6 hours ago

International efforts to stop the accelerating spread of Ebola in West Africa were ramping up Tuesday, but a medical charity warned that the response is still dangerously behind and time is running out to act.

Facing a post-antibiotic world

6 hours ago

It's official. Humanity is racing towards a post-antibiotic era, a time when today's life-saving drugs won't successfully treat common infectious diseases or even infections from minor injuries.

User comments